PROS1 and Familial prostate cancer: Having defined a novel set of biomolecular activities representative of NFκB activation in prostate cancer, two logical next steps would be to 1) experimentally validate their molecular mechanisms of action and 2) evaluate gene sets derived from our extended pathway as potential clinical biomarkers for prostate cancer risk (e.g. in conjunction with criteria such as Gleason 6, low volume PSA < 10).